Investigation of the effect of pentoxifylline on Covid-19
Phase 3
- Conditions
- COVID _19.Multisystem inflammatory syndrome associated with COVID_19U10.9
- Registration Number
- IRCT20170609034406N8
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Positive PCR test for nasopharyngeal sample or certain evidence indicating Covid-19 disease
Moderate to mild symptoms
onset of symptoms within 7 days
Ability to swallow
Age between 18 and 75
Exclusion Criteria
Shock state or multi-organ failure
Chronic liver disease
Chronic kidney disease
Pregnancy and lactation
Participation in other clinical studies
Receiving drugs with severe interaction with pentoxifylline
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method